Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumors and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR).
Aim(s): To gain nurses’ insights on the use and ease of administration of SSA devices, including Somatuline Autogel new device (SA-ND) in Europe and the US.
Materials and methods: Seventy-seven qualified nurses with =3 SSA patients/year were interviewed to gather views regarding SSA injection use. Nurses were timed while preparing and performing test injections with SA-ND and LAR. Attributes of SA-ND and current SSA devices were evaluated and an overall preference score (attributes weighted by importance to nurses) calculated for each.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Hannah Kurth
To read results and conclusion, please login ...
Further abstracts you may be interested in